arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

IOVANCE BIOTHERAPEUTICS, INC.

IOVA
$6.33 ▲ +0.16 (+2.51%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

IOVANCE BIOTHERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6M
Dividend Yield
Revenue Growth 44.8%
Op. Margin -113.5%
ROIC -11.1%
FCF / Share $-188.00
Trailing P/E
Price / Book 3.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$71.43M
↑ +44.8%
Net Income Profit after all expenses
$-79.05M
↑ +32.0%
Operating Margin Operating profit as % of sales
-113.5%
↓ -34.0% 1th
FCF / Share Free cash flow per share
$-188.00
↑ +44.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
15
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 67 quarters